Seagen
Biotechnology, 30th Dr Se, Bothell, , 98021, Washington, 21823, United States, 1001-5000 Employees
Phone Number: 42********
Who is SEAGEN
Targeting Cancer. Transforming Therapies. Seagen is where revolutionary science meets transformative cancer therapy. Seagen is committed to advancing late-stage clinical trials and expand...
Read More
- Headquarters: 21823 30th Dr Se, Bothell, Washington, 98021, United States
- Date Founded: 1998
- Employees: 1001-5000
- Revenue: $1 Billion and Over
- Active Tech Stack: See technologies
- CEO: David Epstein
Industry: Biotechnology
SIC Code: 2836 | NAICS Code: 621111 | Show More
Seagen Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Seagen
Answer: Seagen's headquarters are located at 30th Dr Se, Bothell, , 98021, Washington, 21823, United States
Answer: Seagen's phone number is 42********
Answer: Seagen's official website is https://seagen.com
Answer: Seagen's revenue is $1 Billion and Over
Answer: Seagen's SIC: 2836
Answer: Seagen's NAICS: 621111
Answer: Seagen has 1001-5000 employees
Answer: Seagen is in Biotechnology
Answer: Seagen contact info: Phone number: 42******** Website: https://seagen.com
Answer: Targeting Cancer. Transforming Therapies. Seagen is where revolutionary science meets transformative cancer therapy. Seagen is committed to advancing late-stage clinical trials and expanding the development of its portfolio both in and outside the U.S. to better the health of people with cancer. We are dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. We are focused on discovering, developing, manufacturing and commercializing targeted cancer therapeutics, with antibody-drug conjugates (ADCs) at our core. We work together with urgency to improve and extend the lives of people living with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability, and potency. We are working on expanding the four approved therapies for cancer while advancing new technologies with the potential to generate multiple Investigational New Drug Applications (INDs) that include next-generation ADC technologies and other novel cancer-targeting approaches.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month